Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Blood|December 21, 2011
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaJeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, et al.
Cancer|June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionMeletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Future Oncology (London, England)|January 10, 2024
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practiceXavier Leleu, Hans C Lee, Jeffrey A Zonder, et al.
Patient Preference and Adherence|March 8, 2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United StatesDaniel Auclair, Carol Mansfield, Mark A Fiala, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma ImmunityLawrence G Lum, Archana Thakur, Sri Vidya Kondadasula, et al.
Cancer Medicine|December 18, 2021
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myelomaDarren Pan, Jonathan L Kaufman, Myo Htut, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
Blood|March 28, 2012
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studySuzanne Lentzsch, Amy O'Sullivan, Ryan C Kennedy, et al.
Blood Cancer Journal|February 28, 2019
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)Charalampia Kyriakou, Sean Molloy, Frank Vrionis, et al.
Pageof 6